Ra Capital Management Reveals New Stake in Enanta Pharmaceuticals Inc (ENTA)

Peter Kolchinsky‘s Ra Capital Management disclosed a new position in Enanta Pharmaceuticals Inc (NASDAQ:ENTA). According to a 13G filing, the new positions amounts to 1.54 million shares, which represent 8.00% of the company’s common stock. 

Peter Kolchinsky

Headquartered in Watertown, Massachusetts, Enanta Pharmaceuticals Inc (NASDAQ:ENTA) is a biotechnology company focused on the research and development of small molecule drugs in the infectious disease field. The company aims to discover and develop novel inhibitors designed for use against the HCV (hepatitis C virus). In addition to the HCV programs, Enanta has created Bicyclolides - a class of antibiotics for the treatment of multi-drug-resistant bacteria. In March, 2013, the drug developer raised $56.00 million in an initial public offering, pricing the stock at $14.00 per share.  The same year, the company disclosed net losses of slightly more than $4.00 million with respective losses of $0.67 per share, beating market expectations ($-1.78) by more than 60.00%. Analysts estimate steady earnings growth for the period of 2014, predicting losses per share of $0.30 for the first quarter, but earnings per share of $1.45 for the whole year. In 2015, Enanta Pharmaceuticals Inc (NASDAQ:ENTA) is expected to produce profits per share in the range of $3.00 to a high $16.00 per share. Average consensus recommendation for the company’s stock is “Buy”.

Managed by Mitchell Blutt, Consonance Capital Management is another large shareholder at Enanta Pharmaceuticals, holding more than 850,000 shares of the company as at the end of 2013 – a position worth $23.20 million.

A graduate from Harvard with a Ph.D. in virology, Peter Kolchinsky manages an equity portfolio concentrated almost entirely in the Healthcare Sector. The largest position in the portfolio (15.30%) belongs to Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), in which Kolchinsky’s fund invested $77.60 million, holding nearly 23.40 million shares.

Recently, RA Capital disclosed a new passive stake of 1.44 million shares in Repros Therapeutics Inc (NASDAQ:RPRX). Also, the fund boosted its position in pSivida Corp. (NASDAQ:PSDV) to 2.56 million shares – 6.20% of the company’s common stock.

Disclosure: none

Recommended Reading:

Ra Capital Management Initiates Stake in Furiex Pharmaceuticals Inc (FURX) After the Stock Jumped

Ra Capital Management Lowers Stake in Derma Sciences Inc (DSCI)

Trian Partners Discloses an Increased Position in Ingersoll-Rand PLC (IR)

Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 10 Largest Pharmaceutical Companies In the World

The 10 Most Expensive Android Apps

The 9 Most Expensive Designer Bags in the World

The 7 Most Expensive Real Estate in the World

The 10 Most Expensive eBay Items Ever Sold

The 10 Most Expensive iPhone Apps

The 9 Most Expensive Designer Shoes in the World

The 10 Most Expensive Cigarette Brands

The 10 Most Expensive Law Schools in the US

The 10 Best Wall Street Movies

The 10 Most Expensive Golf Clubs Ever Sold

The 10 Most Expensive Golf Memberships

The 10 Best Disney Characters Ever Created

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!